FI4445900T3 - Terapeuttisia yhdisteitä hiv-virusinfektiota varten - Google Patents
Terapeuttisia yhdisteitä hiv-virusinfektiota vartenInfo
- Publication number
- FI4445900T3 FI4445900T3 FIEP24186082.4T FI24186082T FI4445900T3 FI 4445900 T3 FI4445900 T3 FI 4445900T3 FI 24186082 T FI24186082 T FI 24186082T FI 4445900 T3 FI4445900 T3 FI 4445900T3
- Authority
- FI
- Finland
- Prior art keywords
- inhibitors
- hiv
- modulators
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/095—Compounds containing the structure P(=O)-O-acyl, P(=O)-O-heteroatom, P(=O)-O-CN
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (9)
1. Yhdiste, joka on "Le SUT ; TE : HON ö n on . taisenfarmaseuttisesti hyväksyttävä suola.
2. Terapeuttisesti tehokas määrä patenttivaatimuksen 1, mukaista yhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa käytettäväksi hoidossa.
3. Patenttivaatimuksen 1, mukainen yhdiste tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi menetelmässä ihmisen immuunikatovirus (HIV) -infektion hoitamiseksi tai ehkäisemiseksi sitä tarvitsevalla potilaalla, jolloin menetelmä käsittää yhdisteen tai sen farmaseuttisesti hyväksyttävän suolan, antamisen potilaalle terapeuttisesti tehokkaana määränä.
4. Patenttivaatimuksen 1, mukainen yhdiste tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi menetelmässä ihmisen immuunikatovirus (HIV) -infektion hoitamiseksi paljon hoitoa saaneella potilaalla, jolloin menetelmä käsittää yhdisteen tai sen farmaseuttisesti hyväksyttävän suolan antamisen potilaalle terapeuttisesti tehokkaana — määränä.
EP4445900
2
5. Patenttivaatimuksen 1, mukainen yhdiste tai sen farmaseuttisesti hyväksyttävä suola yhdistelmänä terapeuttisesti tehokkaan määrän yhtä, kahta, kolmea tai neljää muuta terapeuttista ainetta tai niiden farmaseuttisesti hyväksyttävää suolaa kanssa käytettäväksi jommankumman patenttivaatimuksen 3—4 mukaisesti.
6. Patenttivaatimuksen 5, mukaisesti käytettävä yhdistelmä, jolloin yksi, kaksi, kolme tai neljä muuta terapeuttista ainetta valitaan ryhmästä, jonka muodostavat HIV- yhdistelmälääkkeet, muut HIV-lääkkeet, HIV-proteaasin estäjät, HIV:n ei-nukleosidiset tai ei-nukleotidiset käänteistranskriptaasin estäjät, HIV:n nukleosidiset tai nukleotidiset — käänteistranskriptaasin estäjät, HIV:n integraasin estäjät, HIV:n ei-katalyyttisen sitoutumiskohdan (tai allosteeriset) integraasin estäjät, HIV:n sisäänpääsyn estäjät, HIV:n kypsymisen estäjät, HIV-kapsidin estäjät, nukleokapsidiproteiini 7:n (NCp7) estäjät, HIV:n Tat- tai Rev-estäjät, Tat-TAR-P-TEFb:n estäjät, immunomodulaattorit, immunoterapeuttiset aineet, vasta-aine-lääkekonjugaatit, geenimodifioijat, geenieditorit — (kuten CRISPR/Cas9, sinkkisorminukleaasit, homing-nukleaasit, synteettiset nukleaasit, TALENIT), soluhoidot (kuten kimeerisen antigeenireseptorin T-solu, CAR-T ja muokatut T-solureseptorit, TCR-T, autologiset T-soluhoidot, muokatut B-solut, NK-solut), latenssivaiheen kääntävät aineet, immuunipohjaiset hoidot, fosfatidyyli-inositoli-3- kinaasin (PI3K) estäjät, HIV-vasta-aineet, bispesifiset vasta-aineet ja ”vasta-aineen — kaltaiset? terapeuttiset proteiinit, HIV p17 -matriisiproteiinin estäjät, |L-13-antagonistit, peptidyyli-prolyyli-cis-trans-isomeraasi A:n modulaattorit, proteiinidisulfidi-isomeraasin estäjät, komplementti C5a:n reseptorin antagonistit, DNA-metyylitransferaasin estäjä, rasvahapposyntaasin estäjä, HIV:n vif-geenin modulaattorit, Vif-dimerisaation antagonistit, HIV-1-viruksen infektiivisyystekijän estäjät, HIV-1:n Nef-modulaattorit, TNF- — alfa-ligandin estäjät, HIV:n Nef-estäjät, Hck-tyrosiinikinaasimodulaattorit, sekalinjaiset kinaasi-3:n (MLK-3) estäjät, HIV-1:n silmukoinnin estäjät, integriiniantagonistit, nukleoproteiinin estäjät, silmukointitekijän modulaattorit, COMM-domeenin sisältävät proteiini 1:n modulaattorit, HIV-ribonukleaasi H:n estäjät, IFN-antagonistit, retrosykliinimodulaattorit, CD3-antagonistit, CDK-4-estäjät, CDK-6-estäjät, CDK-9- — estäjät, sytokromi P450 3 -estäjät, CXCR4-modulaattorit, dendriittiset ICAM-3:een tarttuvat nonintegriini 1:n estäjät, HIV:n GAG-proteiinin estäjät, HIV:n POL-proteiinin
EP4445900 3 estäjät, komplementtitekijä H:n modulaattorit, ubikitiiniligaasin estäjät, deoksisytidiinikinaasin estäjät, sykliiniriippuvaiset kinaasin estäjät, HPK1 (MAP4K1) - estäjät, proproteiinikonvertaasi PC9:n stimulaattorit, ATP:stä riippuvaiset RNA-helikaasi DDX3X:n estäjät, käänteistranskriptaasin alustuskompleksin estäjät, G6PD- ja NADH- — oksidaasin estäjät, MTOR-kompleksi 1:n estäjät, MTOR-kompleksi 2:n estäjät, P- glykoproteiinimodulaattorit, RNA-polymeraasin modulaattorit, TAT-proteiinin estäjät, prolyyliendopeptidaasin estäjät, fosfolipaasi A2:n estäjät, farmakokineettiset tehostusaineet, HIV-geeniterapia, HIV-rokotteet ja HIV:n vastaiset peptidit tai niiden yhdistelmät.
7. Jommankumman patenttivaatimuksen 5—6, mukaisesti käytettävä yhdistelmä, jossa yksi, kaksi, kolme tai neljä muuta terapeuttista ainetta valitaan ryhmästä, jonka muodostavat HIV-yhdistelmälääkkeet, muut HIV-lääkkeet, HIV-proteaasin estäjät, HIV:n käänteistranskriptaasin estäjät, HIV:n integraasin estäjät, HIV:n ei-katalyyttisen — sitoutumiskohdan (tai allosteeriset) integraasin estäjät, HIV:n sisäänpääsyn (fuusion) estäjät, HIV:n kypsymisen estäjät, latenssivaiheen kääntävät aineet, kapsidin estäjät, immuunipohjaiset hoidot, PI3K-estäjät, HIV-vasta-aineet, bispesifiset vasta-aineet ja ”vasta-aineen kaltaiset” terapeuttiset proteiinit tai mitkä tahansa niiden yhdistelmät.
— 8. Jonkin patenttivaatimuksen 5-7, mukaisesti käytettävä yhdistelmä, jossa yksi, kaksi, kolme tai neljä muuta terapeuttista ainetta on valittu ryhmästä, jonka muodostavat dolutegraviiri, kabotegraviiri, darunaviiri, biktegraviiri, elsulfaviriini, rilpiviriini, abakaviirisulfaatti, tenofoviiri, tenofoviiridisoproksiili, tenofoviiridisoproksiilifumaraatti, tenofoviiridisoproksiilihemifumaraatti, tenofoviirialafenamidi ja —tenofoviirialatenamidihemifumaraatti tai niiden farmaseuttisesti hyväksyttävä suola.
9. Yhdiste tai sen farmaseuttisesti hyväksyttävä suola tai yhdistelmä käytettäväksi jonkin patenttivaatimuksen 3—8, mukaisesti, jolloin potilas on ihminen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285730P | 2021-12-03 | 2021-12-03 | |
| US202263356889P | 2022-06-29 | 2022-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4445900T3 true FI4445900T3 (fi) | 2025-08-05 |
Family
ID=85018817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP24186082.4T FI4445900T3 (fi) | 2021-12-03 | 2022-12-02 | Terapeuttisia yhdisteitä hiv-virusinfektiota varten |
| FIEP22846980.5T FI4440702T3 (fi) | 2021-12-03 | 2022-12-02 | Terapeuttisia yhdisteitä hiv-virusinfektiota varten |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP22846980.5T FI4440702T3 (fi) | 2021-12-03 | 2022-12-02 | Terapeuttisia yhdisteitä hiv-virusinfektiota varten |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11787825B2 (fi) |
| EP (3) | EP4440702B1 (fi) |
| JP (2) | JP7738191B2 (fi) |
| KR (1) | KR20240113577A (fi) |
| AU (2) | AU2022401696B2 (fi) |
| CA (1) | CA3235937A1 (fi) |
| CL (1) | CL2024001582A1 (fi) |
| CO (1) | CO2024006742A2 (fi) |
| CR (1) | CR20240223A (fi) |
| DK (2) | DK4445900T3 (fi) |
| DO (1) | DOP2024000103A (fi) |
| ES (2) | ES3038096T3 (fi) |
| FI (2) | FI4445900T3 (fi) |
| HR (2) | HRP20250929T1 (fi) |
| HU (2) | HUE072195T2 (fi) |
| IL (1) | IL312718A (fi) |
| LT (2) | LT4440702T (fi) |
| MX (1) | MX2024006396A (fi) |
| PE (1) | PE20241341A1 (fi) |
| PL (2) | PL4445900T3 (fi) |
| PT (2) | PT4445900T (fi) |
| SI (2) | SI4445900T1 (fi) |
| TW (2) | TW202412779A (fi) |
| WO (1) | WO2023102239A1 (fi) |
| ZA (1) | ZA202500439B (fi) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| CA3281991A1 (en) | 2018-02-16 | 2025-11-29 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
| JP2021530523A (ja) | 2018-07-16 | 2021-11-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のためのカプシド阻害剤 |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| CN118355020A (zh) * | 2021-12-03 | 2024-07-16 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
| FI4445900T3 (fi) * | 2021-12-03 | 2025-08-05 | Gilead Sciences Inc | Terapeuttisia yhdisteitä hiv-virusinfektiota varten |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| US20250011353A1 (en) * | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Process of preparing hiv capsid inhibitor |
| US20250011352A1 (en) * | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Solid forms |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250120989A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| CN118324623A (zh) * | 2024-04-12 | 2024-07-12 | 丽珠集团福州福兴医药有限公司 | 一种2-甲基-4-乙酰基苯甲酸的合成方法 |
| WO2025240387A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367386A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367381A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240389A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367385A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| CN118561677A (zh) * | 2024-05-16 | 2024-08-30 | 丽珠集团福州福兴医药有限公司 | 一种2-甲基-4-乙酰基苯甲酸的合成方法 |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JP3347723B2 (ja) | 1990-06-13 | 2002-11-20 | グラツィエル，アーノルド | 含リンプロドラッグ |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| AU2001282941C1 (en) | 2000-07-21 | 2016-12-22 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| US7196201B2 (en) | 2001-06-27 | 2007-03-27 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| US7183290B2 (en) | 2001-06-27 | 2007-02-27 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| DE60218511T2 (de) | 2001-10-26 | 2007-10-25 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| WO2004071448A2 (en) | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
| CA2523083C (en) | 2003-04-25 | 2014-07-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| BRPI0508186A (pt) | 2004-02-27 | 2007-08-14 | Schering Corp | compostos como inibidores de ns3 serina protease de vìrus da hepatite c |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| JP2008508291A (ja) | 2004-07-27 | 2008-03-21 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ｈｉｖ剤としてのヌクレオシドホスホネート結合体 |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TWI404537B (zh) | 2005-08-19 | 2013-08-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| AR058379A1 (es) | 2005-12-14 | 2008-01-30 | Bristol Myers Squibb Co | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. |
| CN101466676B (zh) | 2006-04-12 | 2012-07-18 | 默沙东公司 | 吡啶基酰胺类t-型钙通道拮抗剂 |
| AR061838A1 (es) | 2006-07-07 | 2008-09-24 | Gilead Sciences Inc | Moduladores de propiedades farmacocineticas de terapeuticos |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
| US8124811B2 (en) | 2007-03-20 | 2012-02-28 | Allylix, Inc. | Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one |
| EP2139883A4 (en) | 2007-03-23 | 2011-06-22 | Univ Massachusetts | HIV-1 protease inhibitor |
| AP2009005073A0 (en) | 2007-06-29 | 2009-12-31 | Gilead Sciences Inc | Antiviral compounds |
| EA021463B1 (ru) | 2007-06-29 | 2015-06-30 | Джилид Сайэнс, Инк. | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 |
| WO2009010804A1 (en) | 2007-07-19 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
| CA2701594C (en) | 2007-10-24 | 2014-02-18 | Merck Sharp & Dohme Corp. | Heterocycle phenyl amide t-type calcium channel antagonists |
| AU2008317352A1 (en) | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Heterocycle amide T-type calcium channel antagonists |
| KR20100097156A (ko) | 2007-11-16 | 2010-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 사람 면역결핍 바이러스 복제의 억제제 |
| CN102026996B (zh) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
| HUE025528T2 (en) | 2008-04-23 | 2016-05-30 | Gilead Sciences Inc | 1'-substituted carba-nucleoside analogs for antiviral treatment |
| PT2313111E (pt) | 2008-08-01 | 2013-12-05 | Ventirx Pharmaceuticals Inc | Formulações de agonista de receptor do tipo toll e seus usos |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| TW201639852A (zh) | 2008-12-09 | 2016-11-16 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
| SG173822A1 (en) | 2009-02-25 | 2011-09-29 | Bigtec Private Ltd | Probes and primers for detection of chikungunya |
| US8673307B1 (en) | 2009-03-09 | 2014-03-18 | The Rockefeller University | HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120 |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| PL2467377T3 (pl) | 2009-08-18 | 2017-10-31 | Ventirx Pharmaceuticals Inc | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
| WO2011022509A2 (en) | 2009-08-18 | 2011-02-24 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| WO2011049825A1 (en) | 2009-10-22 | 2011-04-28 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| WO2011143772A1 (en) | 2010-05-21 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| BR112012033689A2 (pt) | 2010-07-02 | 2019-09-24 | Gilead Sciences Inc | derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais |
| SG186820A1 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht- 2 -ylacetic acid derivatives to treat aids |
| US20120027752A1 (en) | 2010-07-22 | 2012-02-02 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| PH12013500173A1 (en) | 2010-08-10 | 2017-10-25 | Lupin Ltd | Oral controlled release pharmaceutical compositions of blonanserin |
| MX340290B (es) | 2010-10-01 | 2016-07-04 | Ventirx Pharmaceuticals Inc | Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación. |
| BR112013007678A2 (pt) | 2010-10-01 | 2017-07-04 | Ventirx Pharmaceuticals Inc | método para tratamento de doenças alérgicas |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| US9718796B2 (en) | 2011-01-12 | 2017-08-01 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| BR112013017947A2 (pt) | 2011-01-12 | 2018-12-18 | Array Biopharma Inc | benzoazepinas substituídas como moduladores de receptor toll-like |
| PL3290415T3 (pl) | 2011-03-23 | 2021-07-19 | Trevena, Inc. | Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania |
| LT3590928T (lt) | 2011-04-08 | 2021-08-25 | Janssen Sciences Ireland Unlimited Company | Pirimidino dariniai, skirti virusinės infekcijos gydymui |
| ES2615734T3 (es) | 2011-04-21 | 2017-06-08 | Gilead Sciences, Inc. | Compuestos de benzotiazol y su uso farmacéutico |
| WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
| US9783594B2 (en) | 2011-05-17 | 2017-10-10 | The Rockefeller University | Human immunodeficiency virus neutralizing antibodies and methods of use thereof |
| US8916575B2 (en) | 2011-05-18 | 2014-12-23 | Janssen R&D Ireland | Quinazoline derivatives for the treatment of viral infections and further diseases |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| US9493549B2 (en) | 2011-07-25 | 2016-11-15 | The Rockefeller University | Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth |
| DK2744810T4 (da) | 2011-08-16 | 2023-11-20 | Gilead Sciences Inc | Tenofovir-alafenamid-hemifumarat |
| KR102033802B1 (ko) | 2011-10-07 | 2019-10-17 | 길리애드 사이언시즈, 인코포레이티드 | 항-바이러스 뉴클레오티드 유사체의 제조 방법 |
| CA2858716C (en) | 2011-12-08 | 2021-10-12 | Peter D. Kwong | Neutralizing antibodies to hiv-1 and their use |
| EP2794613B1 (en) | 2011-12-20 | 2017-03-29 | Boehringer Ingelheim International GmbH | Condensed triclyclic compounds as inhibitors of hiv replication |
| KR101699822B1 (ko) | 2011-12-21 | 2017-01-25 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| BR112014019699B1 (pt) | 2012-02-08 | 2021-12-07 | Janssen Sciences Ireland Uc | Derivados de piperidino-pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende |
| CA2866133A1 (en) | 2012-03-05 | 2013-09-12 | Cipla Limited | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine |
| WO2013142324A1 (en) | 2012-03-23 | 2013-09-26 | Usa, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| MX2014005002A (es) | 2012-04-20 | 2014-07-09 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih. |
| GB201213087D0 (en) | 2012-07-24 | 2012-09-05 | Medical Res Council | Inhibition of HIV-1 infection |
| BR112015002524B1 (pt) | 2012-08-10 | 2021-11-03 | Janssen Sciences Ireland Uc | Derivados de alquilpirimidina, composição farmacêutica que os compreende e uso dos mesmos |
| WO2014028931A2 (en) | 2012-08-17 | 2014-02-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| SI2906563T1 (en) | 2012-10-10 | 2018-06-29 | Janssen Sciences Ireland Uc | Derivatives of pyrrolo (3,2-d) pyrimidine for the treatment of viral infections and other diseases |
| CN118955699A (zh) | 2012-10-18 | 2024-11-15 | 洛克菲勒大学 | 广泛中和性抗hiv抗体 |
| MY171115A (en) | 2012-11-16 | 2019-09-26 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| US9951106B2 (en) | 2012-12-04 | 2018-04-24 | University Of Maryland, Baltimore | Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb |
| MX344879B (es) | 2012-12-21 | 2017-01-11 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. |
| RU2015131006A (ru) | 2012-12-27 | 2017-01-30 | Джапан Тобакко Инк. | ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ) |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| JP5860197B1 (ja) | 2013-01-09 | 2016-02-16 | ギリアード サイエンシーズ， インコーポレイテッド | ウイルス感染症を処置するための治療用化合物 |
| PT2943487T (pt) | 2013-01-09 | 2016-12-15 | Gilead Sciences Inc | Heteroarilos de 5 membros e sua utilização como agentes antivirais |
| WO2014110323A1 (en) | 2013-01-11 | 2014-07-17 | Johnson Controls Technology Company | Vehicle interior component having a wireless charging indicator |
| UA118751C2 (uk) | 2013-02-21 | 2019-03-11 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Похідні 2-амінопіримідину для лікування вірусних інфекцій |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| WO2015048462A1 (en) | 2013-09-27 | 2015-04-02 | Duke University | Human monoclonal antibodies |
| SG11201603217SA (en) | 2013-10-24 | 2016-05-30 | Bristol Myers Squibb Co | Inhibitors of human immunodeficiency virus replication |
| WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| WO2015117008A2 (en) | 2014-01-31 | 2015-08-06 | The Rockefeller University | Broadly neutralizing anti-hiv antibodies and epitope therefor |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| WO2016014484A1 (en) | 2014-07-21 | 2016-01-28 | The Rockefeller University | Combination of broadly neutralizing hiv antibodies and viral inducers |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| WO2016040084A1 (en) | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| BR112017013491A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de pirimidina fundida para o tratamento de hiv |
| NZ733125A (en) | 2014-12-24 | 2018-06-29 | Gilead Sciences Inc | Isoquinoline compounds for the treatment of hiv |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| EP3722297A1 (en) | 2015-03-04 | 2020-10-14 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| WO2016149710A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
| HRP20200583T1 (hr) | 2015-03-20 | 2020-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Protutijela koja neutraliziraju gp120 i njihova upotreba |
| US20180072997A1 (en) | 2015-04-23 | 2018-03-15 | ViiV HEATHCARE UK (NO.5) LIMITED | Inhibitors of human immunodeficiency virus replication |
| PT3286166T (pt) | 2015-04-23 | 2020-08-18 | Viiv Healthcare Uk No 5 Ltd | Inibidores de replicação do vírus da imunodeficiência humana |
| TWI716405B (zh) | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
| WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
| SI3191470T1 (sl) | 2015-07-06 | 2019-04-30 | Gilead Sciences, Inc. | Modulatorji COT in postopki njihove uporabe |
| AU2016219668B2 (en) | 2015-08-26 | 2021-10-21 | Matthew Graeme Dridan | A vacuum lift attachment |
| US20180263985A1 (en) | 2015-09-15 | 2018-09-20 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| WO2017096221A1 (en) | 2015-12-02 | 2017-06-08 | The Rockefeller University | Bispecific anti-hiv broadly neutralizing antibodies |
| MA43389A (fr) | 2015-12-02 | 2021-05-12 | Agenus Inc | Anticorps anti-ox40 et leurs procédés d'utilisation |
| CA3007022A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
| WO2017096276A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| WO2017096182A1 (en) | 2015-12-03 | 2017-06-08 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| JP6732915B2 (ja) | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ， インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| CN107022027B (zh) | 2016-02-02 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
| CN107033241B (zh) | 2016-02-03 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
| BR112018071678B1 (pt) * | 2016-08-19 | 2021-01-26 | Gilead Sciences, Inc. | compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| ES2906581T3 (es) | 2016-09-02 | 2022-04-19 | Gilead Sciences Inc | Compuestos moduladores de los receptores tipo Toll |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
| UY37710A (es) | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| WO2018237148A1 (en) | 2017-06-21 | 2018-12-27 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
| AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
| WO2019087016A1 (en) | 2017-10-30 | 2019-05-09 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in hiv therapy |
| KR102587510B1 (ko) | 2018-02-15 | 2023-10-11 | 길리애드 사이언시즈, 인코포레이티드 | 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도 |
| CA3281991A1 (en) | 2018-02-16 | 2025-11-29 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
| US10911396B2 (en) | 2018-06-28 | 2021-02-02 | Paypal, Inc. | Mid-tier messaging system |
| SG11202012043RA (en) | 2018-07-03 | 2021-01-28 | Gilead Sciences Inc | Antibodies that target hiv gp120 and methods of use |
| JP2021530523A (ja) | 2018-07-16 | 2021-11-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のためのカプシド阻害剤 |
| TWI766172B (zh) | 2018-07-30 | 2022-06-01 | 美商基利科學股份有限公司 | 抗hiv化合物 |
| SI3938047T1 (sl) | 2019-03-22 | 2022-10-28 | Gilead Sciences, Inc. | Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba |
| EP4643882A2 (en) | 2019-11-26 | 2025-11-05 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| FI4445900T3 (fi) * | 2021-12-03 | 2025-08-05 | Gilead Sciences Inc | Terapeuttisia yhdisteitä hiv-virusinfektiota varten |
| WO2023102523A1 (en) * | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
-
2022
- 2022-12-02 FI FIEP24186082.4T patent/FI4445900T3/fi active
- 2022-12-02 DK DK24186082.4T patent/DK4445900T3/da active
- 2022-12-02 PL PL24186082.4T patent/PL4445900T3/pl unknown
- 2022-12-02 JP JP2024531110A patent/JP7738191B2/ja active Active
- 2022-12-02 SI SI202230161T patent/SI4445900T1/sl unknown
- 2022-12-02 HU HUE22846980A patent/HUE072195T2/hu unknown
- 2022-12-02 SI SI202230160T patent/SI4440702T1/sl unknown
- 2022-12-02 ES ES24186082T patent/ES3038096T3/es active Active
- 2022-12-02 KR KR1020247021978A patent/KR20240113577A/ko active Pending
- 2022-12-02 PL PL22846980.5T patent/PL4440702T3/pl unknown
- 2022-12-02 HR HRP20250929TT patent/HRP20250929T1/hr unknown
- 2022-12-02 HU HUE24186082A patent/HUE072170T2/hu unknown
- 2022-12-02 EP EP22846980.5A patent/EP4440702B1/en active Active
- 2022-12-02 LT LTEPPCT/US2022/051734T patent/LT4440702T/lt unknown
- 2022-12-02 FI FIEP22846980.5T patent/FI4440702T3/fi active
- 2022-12-02 TW TW112147542A patent/TW202412779A/zh unknown
- 2022-12-02 MX MX2024006396A patent/MX2024006396A/es unknown
- 2022-12-02 PT PT241860824T patent/PT4445900T/pt unknown
- 2022-12-02 EP EP25163526.4A patent/EP4566608A3/en active Pending
- 2022-12-02 AU AU2022401696A patent/AU2022401696B2/en active Active
- 2022-12-02 WO PCT/US2022/051734 patent/WO2023102239A1/en not_active Ceased
- 2022-12-02 PT PT228469805T patent/PT4440702T/pt unknown
- 2022-12-02 CA CA3235937A patent/CA3235937A1/en active Pending
- 2022-12-02 EP EP24186082.4A patent/EP4445900B1/en active Active
- 2022-12-02 US US18/061,375 patent/US11787825B2/en active Active
- 2022-12-02 CR CR20240223A patent/CR20240223A/es unknown
- 2022-12-02 PE PE2024001212A patent/PE20241341A1/es unknown
- 2022-12-02 TW TW111146359A patent/TW202337439A/zh unknown
- 2022-12-02 ES ES22846980T patent/ES3037983T3/es active Active
- 2022-12-02 HR HRP20250928TT patent/HRP20250928T1/hr unknown
- 2022-12-02 IL IL312718A patent/IL312718A/en unknown
- 2022-12-02 LT LTEP24186082.4T patent/LT4445900T/lt unknown
- 2022-12-02 DK DK22846980.5T patent/DK4440702T3/da active
-
2023
- 2023-08-22 US US18/236,532 patent/US12187753B2/en active Active
-
2024
- 2024-05-27 CL CL2024001582A patent/CL2024001582A1/es unknown
- 2024-05-27 DO DO2024000103A patent/DOP2024000103A/es unknown
- 2024-05-27 CO CONC2024/0006742A patent/CO2024006742A2/es unknown
- 2024-10-21 US US18/921,239 patent/US20250179102A1/en active Pending
-
2025
- 2025-01-14 ZA ZA2025/00439A patent/ZA202500439B/en unknown
- 2025-09-01 JP JP2025144760A patent/JP2025172126A/ja active Pending
- 2025-09-17 AU AU2025234182A patent/AU2025234182A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4445900T3 (fi) | Terapeuttisia yhdisteitä hiv-virusinfektiota varten | |
| IL268282B2 (en) | hiv inhibitory compounds | |
| US11318119B2 (en) | HIV protease inhibitors | |
| JP2019528280A5 (fi) | ||
| JPWO2023102239A5 (fi) | ||
| Sliepen et al. | Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers | |
| JPWO2020092621A5 (fi) | ||
| CN109996815A (zh) | 以cd4抗体于稳定接受haart治疗的患者进行hiv感染的治疗和持续性的病毒缓解 | |
| AU2021320236B2 (en) | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use | |
| US20170296601A1 (en) | Compositions and Methods for Treating an Immunodeficiency Virus Infection | |
| Menéndez-Arias et al. | An update on antiretroviral therapy | |
| EP3700573A1 (en) | Methods of treating patients co-infected with a virus and tuberculosis | |
| JP2025128082A (ja) | Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン | |
| US20250057826A1 (en) | Weekly regimen for hiv | |
| WO2017205585A1 (en) | Combinations and uses treatments thereof | |
| JPWO2023102529A5 (fi) | ||
| Armbruster | HIV-1 infection: recent developments in treatment and current management strategies | |
| Majewska et al. | Antiviral medication in sexually transmitted diseases. Part II: HIV | |
| WO2019016679A1 (en) | Combination drug therapy | |
| AR117709A2 (es) | Composición farmacéutica que comprende un compuesto de 1h-indazol substituido, dicho compuesto y formulación parenteral de la misma | |
| WO2018051250A1 (en) | Combination comprising tenofovir alafenamide, bictegravir and 3tc | |
| WO2018042332A1 (en) | Combinations and uses and treatments thereof | |
| US20220257619A1 (en) | Long-acting formulations of tenofovir alafenamide | |
| JPWO2023086399A5 (fi) | ||
| TW202408576A (zh) | 用於廣泛中和抗體之給藥及排程方案 |